N/A
N=56
Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications
HIV Infections
Bottom Line
View on ClinicalTrials.gov: NCT00433992 ↗Enrolled (actual)
56
Serious AEs
3.6%
Results posted
Jul 2017
Primary outcome: Primary: Change in Mitochondrial Activity — 1250; 1312; 1150; 1125 copies/cell
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Primary completion
- Oct 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mitochondrial Activity |
1250; 1312; 1150; 1125 | — |
| SECONDARY Change in Fat Apoptosis |
906; 1479 | — |
Summary
The purpose of this study is to observe the effects of certain anti-HIV medications on mitochondrial activity and fat cell death. This study will enroll participants from another study, ACTG A5202, who are on treatment regimens that do not include zidovudine, stavudine, or other thymidine-containing anti-HIV medications.
Eligibility Criteria
Inclusion Criteria
- HIV-infected
- Enrolling in ACTG A5202 and its metabolic substudy ACTG A5224
Exclusion Criteria
- Bleeding problems
- Cannot undergo fat biopsies
- Require aspirin anytime in the 7-day period prior to each biopsy
Data sourced from ClinicalTrials.gov (NCT00433992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.